hydroxyproline has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, X; Lin, J; Peng, L; Wu, Q; Zhai, Y; Zuo, Z | 1 |
1 other study(ies) available for hydroxyproline and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Fluvastatin decreases cardiac fibrosis possibly through regulation of TGF-beta(1)/Smad 7 expression in the spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Blotting, Western; Cardiomegaly; Cholesterol; Collagen; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fibrosis; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyproline; Immunohistochemistry; Indoles; Lipids; Male; Myocardium; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reverse Transcriptase Polymerase Chain Reaction; Smad7 Protein; Transforming Growth Factor beta1 | 2008 |